156 related articles for article (PubMed ID: 38254240)
1. Increased risk of contralateral breast cancer for BRCA1/2 wild-type, high-risk Korean breast cancer patients: a retrospective cohort study.
Kang E; Jung JJ; Lim C; Kim HK; Lee HB; Han W; Moon HG
Breast Cancer Res; 2024 Jan; 26(1):14. PubMed ID: 38254240
[TBL] [Abstract][Full Text] [Related]
2. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers in a large cohort of unselected Chinese breast cancer patients.
Su L; Xu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Int J Cancer; 2020 Jun; 146(12):3335-3342. PubMed ID: 32037537
[TBL] [Abstract][Full Text] [Related]
3. Contralateral breast cancer after radiotherapy among BRCA1 and BRCA2 mutation carriers: a WECARE study report.
Bernstein JL; Thomas DC; Shore RE; Robson M; Boice JD; Stovall M; Andersson M; Bernstein L; Malone KE; Reiner AS; Lynch CF; Capanu M; Smith SA; Tellhed L; Teraoka SN; Begg CB; Olsen JH; Mellemkjaer L; Liang X; Diep AT; Borg A; Concannon P; Haile RW;
Eur J Cancer; 2013 Sep; 49(14):2979-85. PubMed ID: 23706288
[TBL] [Abstract][Full Text] [Related]
4. Impact of BRCA mutation on the survival and risk of contralateral breast cancer in Asian breast cancer patients.
Lin PH; Chen SC; Tseng LM; Chang KJ; Huang AC; Cheng KC; Yang K; Wu HC; Chao TY; Chang YC; Lin PC; Kuo WH; Kuo WL; Lin CH; Chen HM; Yeh DC; Liu LC; Liu CY; Wang MY; Lo C; Lu YS; Huang CS
Breast Cancer Res Treat; 2022 Apr; 192(3):629-637. PubMed ID: 35113257
[TBL] [Abstract][Full Text] [Related]
5. Cyclin D1 expression analysis in familial breast cancers may discriminate BRCAX from BRCA2-linked cases.
Colombo M; Giarola M; Mariani L; Ripamonti CB; De Benedetti V; Sardella M; Losa M; Manoukian S; Peissel B; Pierotti MA; Pilotti S; Radice P
Mod Pathol; 2008 Oct; 21(10):1262-70. PubMed ID: 18327210
[TBL] [Abstract][Full Text] [Related]
6. Impact of Age at Primary Breast Cancer on Contralateral Breast Cancer Risk in BRCA1/2 Mutation Carriers.
van den Broek AJ; van 't Veer LJ; Hooning MJ; Cornelissen S; Broeks A; Rutgers EJ; Smit VT; Cornelisse CJ; van Beek M; Janssen-Heijnen ML; Seynaeve C; Westenend PJ; Jobsen JJ; Siesling S; Tollenaar RA; van Leeuwen FE; Schmidt MK
J Clin Oncol; 2016 Feb; 34(5):409-18. PubMed ID: 26700119
[TBL] [Abstract][Full Text] [Related]
7. BRCA-CRisk: A Contralateral Breast Cancer Risk Prediction Model for
Sun J; Chu F; Pan J; Zhang Y; Yao L; Chen J; Hu L; Zhang J; Xu Y; Wang X; Cao W; Xie Y
J Clin Oncol; 2023 Feb; 41(5):991-999. PubMed ID: 36480783
[TBL] [Abstract][Full Text] [Related]
8. Outcomes and risk of subsequent breast events in breast-conserving surgery patients with BRCA1 and BRCA2 mutation.
Ye F; Huang L; Lang G; Hu X; Di G; Shao Z; Cao A
Cancer Med; 2020 Mar; 9(5):1903-1910. PubMed ID: 31912664
[TBL] [Abstract][Full Text] [Related]
9. High risk of contralateral breast carcinoma in women with hereditary/familial non-BRCA1/BRCA2 breast carcinoma.
Shahedi K; Emanuelsson M; Wiklund F; Gronberg H
Cancer; 2006 Mar; 106(6):1237-42. PubMed ID: 16475207
[TBL] [Abstract][Full Text] [Related]
10. Risk of asynchronous contralateral breast cancer in noncarriers of BRCA1 and BRCA2 mutations with a family history of breast cancer: a report from the Women's Environmental Cancer and Radiation Epidemiology Study.
Reiner AS; John EM; Brooks JD; Lynch CF; Bernstein L; Mellemkjær L; Malone KE; Knight JA; Capanu M; Teraoka SN; Concannon P; Liang X; Figueiredo JC; Smith SA; Stovall M; Pike MC; Haile RW; Thomas DC; Begg CB; Bernstein JL
J Clin Oncol; 2013 Feb; 31(4):433-9. PubMed ID: 23269995
[TBL] [Abstract][Full Text] [Related]
11. BRCA1/BRCA2 mutations in Japanese women with ductal carcinoma in situ.
Liu Y; Ide Y; Inuzuka M; Tazawa S; Kanada Y; Matsunaga Y; Kuwayama T; Sawada T; Akashi-Tanaka S; Nakamura S
Mol Genet Genomic Med; 2019 Mar; 7(3):e493. PubMed ID: 30652428
[TBL] [Abstract][Full Text] [Related]
12. Prevalence and clinical characterization of BRCA1 and BRCA2 mutations in Korean patients with epithelial ovarian cancer.
Paik ES; Heo EJ; Choi CH; Kim JH; Kim JW; Kim YM; Park SY; Lee JW; Kim JW; Kim BG
Cancer Sci; 2021 Dec; 112(12):5055-5067. PubMed ID: 34657357
[TBL] [Abstract][Full Text] [Related]
13. Breast cancer risk in BRCA1/2 mutation carriers and noncarriers under prospective intensified surveillance.
Engel C; Fischer C; Zachariae S; Bucksch K; Rhiem K; Giesecke J; Herold N; Wappenschmidt B; Hübbel V; Maringa M; Reichstein-Gnielinski S; Hahnen E; Bartram CR; Dikow N; Schott S; Speiser D; Horn D; Fallenberg EM; Kiechle M; Quante AS; Vesper AS; Fehm T; Mundhenke C; Arnold N; Leinert E; Just W; Siebers-Renelt U; Weigel S; Gehrig A; Wöckel A; Schlegelberger B; Pertschy S; Kast K; Wimberger P; Briest S; Loeffler M; Bick U; Schmutzler RK;
Int J Cancer; 2020 Feb; 146(4):999-1009. PubMed ID: 31081934
[TBL] [Abstract][Full Text] [Related]
14. Hormone receptor status of a first primary breast cancer predicts contralateral breast cancer risk in the WECARE study population.
Reiner AS; Lynch CF; Sisti JS; John EM; Brooks JD; Bernstein L; Knight JA; Hsu L; Concannon P; Mellemkjær L; Tischkowitz M; Haile RW; Shen R; Malone KE; Woods M; Liang X; Morrow M; Bernstein JL;
Breast Cancer Res; 2017 Jul; 19(1):83. PubMed ID: 28724391
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer.
Reding KW; Bernstein JL; Langholz BM; Bernstein L; Haile RW; Begg CB; Lynch CF; Concannon P; Borg A; Teraoka SN; Törngren T; Diep A; Xue S; Bertelsen L; Liang X; Reiner AS; Capanu M; Malone KE;
Breast Cancer Res Treat; 2010 Sep; 123(2):491-8. PubMed ID: 20135344
[TBL] [Abstract][Full Text] [Related]
16. Prevalence and oncologic outcomes of BRCA 1/2 mutations in unselected triple-negative breast cancer patients in Korea.
Ryu JM; Choi HJ; Kim I; Nam SJ; Kim SW; Yu J; Lee SK; Choi DH; Park YH; Kim JW; Seo JS; Park JH; Lee JE; Kim SW;
Breast Cancer Res Treat; 2019 Jan; 173(2):385-395. PubMed ID: 30350268
[TBL] [Abstract][Full Text] [Related]
17. Contralateral Breast Cancer and Ipsilateral Breast Tumor Recurrence in
Yoon KH; Chae S; Kang E; Shin HC; Kim JH; Kim IA; Park SY; Kim SW; Kim EK
J Breast Cancer; 2019 Dec; 22(4):587-598. PubMed ID: 31897332
[TBL] [Abstract][Full Text] [Related]
18. The risk of contralateral breast cancer in patients from BRCA1/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort study.
Rhiem K; Engel C; Graeser M; Zachariae S; Kast K; Kiechle M; Ditsch N; Janni W; Mundhenke C; Golatta M; Varga D; Preisler-Adams S; Heinrich T; Bick U; Gadzicki D; Briest S; Meindl A; Schmutzler RK
Breast Cancer Res; 2012 Dec; 14(6):R156. PubMed ID: 23216834
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of BRCA1 and BRCA2 Mutations Among High-risk Bahraini Patients with Breast Cancer.
Bukamal Z; AlRayes A
Gulf J Oncolog; 2023 May; 1(42):22-25. PubMed ID: 37283256
[TBL] [Abstract][Full Text] [Related]
20. Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study.
Akdeniz D; van Barele M; Heemskerk-Gerritsen BAM; Steyerberg EW; Hauptmann M; ; van de Beek I; van Engelen K; Wevers MR; Gómez García EB; Ausems MGEM; Berger LPV; van Asperen CJ; Adank MA; Collée MJ; Stommel-Jenner DJ; Jager A; Schmidt MK; Hooning MJ
Breast; 2022 Feb; 61():98-107. PubMed ID: 34929424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
